Four more combination trials of interest in cancer research that may be worth watching out for
Four pretty cool approaches to combination cancer immunotherapy stood out at #ESMO16 in Copenhagen...
Can biomarkers help us improve clinical trial outcomes?
How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?
Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented
Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…
Commentary on Sunday at ESMO16 with a focus on the lung cancer data in the Presidential Symposium
Commentary on Day 2 at ESMO16
What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.
Commentary on Day 1 at ESMO 2016 Congress in Copenhagen.
A look at some of the key breast cancer abstracts to watch out for at #ESMO16 in Copenhagen
Five key approaches in developmental therapeutics in the spotlight at ESMO16
A look at 9 key abstracts in ovarian cancer at #ESMO16 and what to expect
What can we expect in Head & Neck cancer at #ESMO16 in Copenhagen?
A look at what to expect from the lung cancer late breakers at #ESMO16 - are there any surprises or controversies?
Overcoming barriers to resistance in epithelial cancers - a look at a novel oncogenic target
